Compare Entegris Inc (ENTG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Smith & Nephew plc — how do they compare? Entegris Inc trades at $163.9 (market cap $24.78B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: Entegris Inc is far larger — about 2.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Smith & Nephew plc for 120 Days on average.
| ENTG | SNN | |
|---|---|---|
Market Cap | $24.78B | $11.10B |
Volume | 2,648,320 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $184.00 | $37.17 |
52-Week Low | $68.80 | $26.42 |
Typical Hold Time | 41 Days | 120 Days |
Enterprise Value | $27.99B | $14.13B |
Dividend Yield | 0.25% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.
The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
